PIK3CA and breast carcinoma: Arsenic and colleagues compared the results obtained by Sanger sequencing and next-generation sequencing (NGS) for PIK3CA hotspot mutations in exons 9 and 20 in 184 breast cancer samples, reporting a concordance rate of 98.4% (n = 52 mutated cases) (50).